Research graph
References from Population differences in the associations between chromosomal abnormalities and overall survival of multiple myeloma. Local targets link to admitted publications; unresolved targets remain external evidence.
Cancer statistics, 2022
10.3322/caac.21708 · 2022 · External reference
Multiple myeloma current treatment algorithms
10.1038/s41408-020-00359-2 · 2020 · External reference
Racial disparities in incidence and outcome in multiple myeloma: a population-based study
10.1182/blood-2010-07-298760 · 2010 · External reference
Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States
10.1182/bloodadvances.2016002493 · 2017 · External reference
With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study
10.1182/blood.2019000406 · 2019 · External reference
Superior survival in African American patients who underwent autologous stem cell transplantation for multiple myeloma
10.1016/j.clml.2019.04.019 · 2019 · External reference
Annual report to the nation on the status of cancer, part 1: national cancer statistics
10.1002/cncr.34479 · 2022 · External reference
The multiple myelomas — current concepts in cytogenetic classification and therapy
10.1038/s41571-018-0018-y · 2018 · External reference
Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines 2016
10.1001/jamaoncol.2016.5763 · 2017 · External reference
Novel approaches to therapy in CML
10.1182/asheducation-2017.1.115 · 2017 · External reference
Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management
10.1002/ajh.24607 · 2017 · External reference
Interpretation of cytogenetic results in multiple myeloma for clinical practice
10.1038/bcj.2015.92 · 2015 · External reference
Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response
10.1038/s41408-020-00348-5 · 2020 · External reference
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy
10.1182/blood-2005-04-1411 · 2005 · External reference
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy
10.1038/sj.leu.2404516 · 2007 · External reference
(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs
10.1038/bcj.2015.6 · 2015 · External reference
Gain of chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone
10.1038/s41408-019-0254-0 · 2019 · External reference
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
10.1182/blood-2016-01-631200 · 2016 · External reference
Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study
10.1038/bcj.2014.91 · 2015 · External reference
Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry
10.1038/s41408-018-0132-1 · 2018 · External reference
Body mass index and overall survival of patients with newly diagnosed multiple myeloma
10.3390/cancers14215331 · 2022 · External reference
Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myeloma
10.1186/s13045-022-01327-y · 2022 · External reference
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
10.1016/s1470-2045(14)70442-5 · 2014 · External reference
Unresolved reference
2016 · External reference
A More accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation
10.7326/0003-4819-130-6-199903160-00002 · 1999 · External reference
Multiple myeloma: 2022 update on diagnosis, risk-stratification and management
10.1002/ajh.26590 · 2022 · External reference
Prognostic features of multiple myeloma
10.1016/j.beha.2005.01.012 · 2005 · External reference
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
10.1038/leu.2009.174 · 2009 · External reference
Racial differences in treatment and outcomes in multiple myeloma: a Multiple Myeloma Research Foundation analysis
10.1038/s41408-020-00347-6 · 2020 · External reference
Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group
10.1200/jco.2015.61.2267 · 2015 · External reference
IMWG consensus on risk stratification in multiple myeloma
10.1038/leu.2013.247 · 2014 · External reference
High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions
10.1038/s41408-022-00679-5 · 2022 · External reference
Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma
10.1038/sj.leu.2404403 · 2006 · External reference
Multiple myeloma with high-risk cytogenetics and its treatment approach
10.1007/s12185-022-03353-5 · 2022 · External reference
Bortezomib-based induction therapy followed by autologous stem cell transplantation and maintenance therapy with bortezomib improves outcome in myeloma patients with gain 1q21 and t(4;14) - a subgroup analysis of the HOVON-65/GMMG-HD4 trial
10.1182/blood.v116.21.305.305 · 2010 · External reference
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials
10.1200/jco.2012.48.4626 · 2013 · External reference
Impact of black race on peripheral neuropathy in patients with newly diagnosed multiple myeloma receiving bortezomib induction
10.1200/op.22.00781 · 2023 · External reference
Impact of race on bortezomib-induced peripheral neuropathy
2017 · External reference
Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma
10.1038/bcj.2017.83 · 2017 · External reference
Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience
10.1182/blood-2014-07-587964 · 2015 · External reference
Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach
10.1182/blood-2012-07-443606 · 2013 · External reference
Race-based differences in routine cytogenetic profiles of patients with multiple myeloma
10.1111/bjh.13950 · 2017 · External reference
Guiding the global evolution of cytogenetic testing for hematologic malignancies
10.1182/blood.2021014309 · 2022 · External reference
Variability in cytogenetic testing for multiple myeloma: a comprehensive analysis from across the United States
10.1200/jop.19.00639 · 2020 · External reference
European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms
10.1038/s41375-019-0378-z · 2019 · External reference
